Neo Ivy Capital Management Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Neo Ivy Capital Management cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 60.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,956 shares of the medical research company's stock after selling 2,946 shares during the quarter. Neo Ivy Capital Management's holdings in Charles River Laboratories International were worth $361,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Optiver Holding B.V. purchased a new stake in Charles River Laboratories International during the 4th quarter valued at about $37,000. GeoWealth Management LLC grew its position in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in Charles River Laboratories International during the 4th quarter valued at about $48,000. Tortoise Investment Management LLC grew its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. Finally, Huntington National Bank grew its position in Charles River Laboratories International by 120.6% during the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after purchasing an additional 164 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRL. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their price target for the company from $188.00 to $182.00 in a report on Friday. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a report on Wednesday, May 14th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Finally, Barclays raised their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and a consensus price target of $171.85.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Trading Up 1.5%

NYSE CRL traded up $2.09 on Tuesday, hitting $138.82. 800,873 shares of the stock were exchanged, compared to its average volume of 993,202. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a fifty day moving average price of $131.30 and a two-hundred day moving average price of $162.22. The firm has a market capitalization of $6.82 billion, a P/E ratio of 925.47, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.27 earnings per share. Research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).